Leo Pharma to test tralokinumab with new device in phase III study

Although Leo Pharma’s atopic eczema treatment tralokinumab was only recently approved by the FDA 8 months behind schedule, the company is now initiating a late-stage study to investigate the drug with a new device. A syringe component was originally behind the delay.

Photo: Leo Pharma / PR

The US Food and Drug Administration (FDA) approved Leo Pharma’s great growth hope, tralokinumab, shortly before the New Year. Leo Pharma is now beginning to roll out the drug in the US.

This hasn’t stopped the pharmaceutical company from developing the treatment further, including the way patients are treated with the drug. Leo Pharma has just registered a new phase III trial with tralokinumab administered as subcutaneous injection using something only described as ”device A.”

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs